Showing 1 - 10 of 15
The resource-based view of the firm suggests that direct control over unique assets can form the basis of sustained competitive advantage. In contrast, the papers presented in this Special Issue examine the payoffs to cross-boundary resource management. These papers demonstrate the potency of...
Persistent link: https://www.econbiz.de/10005200281
Previous studies have analyzed how incumbents may falter when they focus too narrowly on satisfying the needs of current customers at the expense of pursuing innovations that will ensure future market leadership. This paper examines this 'dilemma' faced by incumbents and considers cases where...
Persistent link: https://www.econbiz.de/10005443180
Considers firms’ management of knowledge creation, diffusion and implementation. In particular, examines the diffusion link in this chain and presents a new framework where an ocean of ideas flows much like an ocean current. Through its past innovative activity and its employees’...
Persistent link: https://www.econbiz.de/10014880220
Persistent link: https://www.econbiz.de/10013162782
Persistent link: https://www.econbiz.de/10011665268
Persistent link: https://www.econbiz.de/10011735951
Persistent link: https://www.econbiz.de/10012214564
What are the forces that are driving firms and industries to globalize their operations? This volume explores how specific industries have organized their global operations through case studies of seven manufacturing industries: garments and textiles, automobiles and auto parts, televisions,...
Persistent link: https://www.econbiz.de/10014477973
In this paper, we employ three simple theoretical models of nonprofit hospitals to investigate equilibrium behavior when hospitals compete. Utilizing a differentiated Bertrand model, we examine how prices, quantity of patients served, service to the uninsured, and quality of care are affected as...
Persistent link: https://www.econbiz.de/10014587519
Although pharmaceutical counterfeiting incidents can be traced back thousands of years, it has been downplayed and even dismissed by pharmaceutical manufacturers in the past. That has changed. Pharmaceutical firms are newly dedicated to eradicate counterfeits globally and spending more money on...
Persistent link: https://www.econbiz.de/10005443224